Xenetic Biosciences Inc. (XBIO)
NASDAQ: XBIO
· Real-Time Price · USD
2.86
-0.06 (-2.22%)
At close: Aug 15, 2025, 3:58 PM
2.91
1.75%
After-hours: Aug 15, 2025, 04:04 PM EDT
Xenetic Biosciences Cash Flow Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Net Income | -688.7K | -903.14K | -1.05M | -436.67K | -1.27M | -1.2M | -1.17M | -1.06M | -1.05M | -856.55K | -1.48M | -804.02K | -2.67M | -1.59M | -1.84M | -1.35M | -1.11M | -1.35M |
Depreciation & Amortization | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 19.09K | 7.96K | 9.61K | 9.47K | 9.28K | 9.04K | 8.75K | 8.41K |
Stock-Based Compensation | 15.68K | 19.25K | 25.11K | 27.54K | 42.1K | 77.07K | 74.58K | 70.27K | 69.39K | 68.85K | 118.65K | 137.36K | 135.87K | 119.59K | 113.1K | 111.13K | 109.92K | 76.28K |
Other Working Capital | -108.33K | 108.33K | 470.56K | 528.29K | -164.34K | 51.78K | 562.81K | -161.53K | -302.5K | -97.94K | 101.93K | -192.25K | 276.89K | -265.31K | -39.01K | 42.01K | 110.79K | -109.73K |
Other Non-Cash Items | 171.19K | n/a | n/a | n/a | n/a | n/a | n/a | -126.92K | 54.44K | 285.64K | 469.66K | 381.6K | 1.3M | 486.9K | 461.19K | -26.11K | -23K | 241.32K |
Deferred Income Tax | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -381.6K | n/a | n/a | -461.19K | n/a | n/a | n/a |
Change in Working Capital | 118K | -118K | 355.42K | -49.9K | 706.77K | -41.31K | 303.9K | 35.66K | -287.55K | -314.74K | 124.23K | -420.57K | 492.81K | -623.15K | 260.6K | 197.34K | 261.2K | -257.94K |
Operating Cash Flow | -383.83K | -1M | -673.99K | -459.04K | -525.1K | -1.16M | -793.03K | -949.63K | -1.27M | -1.1M | -750.91K | -1.08M | -728.9K | -2.09M | -1.46M | -1.03M | -726.81K | -1.52M |
Capital Expenditures | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cash Acquisitions | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -500K | n/a | n/a | n/a | n/a | n/a |
Purchase of Investments | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Sales Maturities Of Investments | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Investing Acitivies | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -500K | n/a | -500K | n/a | n/a | n/a | n/a | n/a |
Investing Cash Flow | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -500K | n/a | -500K | n/a | n/a | n/a | n/a | n/a |
Debt Repayment | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Common Stock Repurchased | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 1.29M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Dividend Paid | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Financial Acitivies | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -805K | n/a | n/a | n/a | 3.68K | 11.45M | n/a | n/a |
Financial Cash Flow | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -805K | n/a | n/a | n/a | 11.45M | 11.45M | n/a | n/a |
Net Cash Flow | -383.83K | -1M | -673.99K | -459.04K | -525.1K | -1.16M | -793.03K | -949.63K | -1.27M | -1.1M | -750.91K | -1.08M | -1.23M | -2.09M | -1.46M | 10.42M | -726.81K | -1.52M |
Free Cash Flow | -383.83K | -1M | -673.99K | -459.04K | -525.1K | -1.16M | -793.03K | -949.63K | -1.27M | -1.1M | -750.91K | -1.08M | -728.9K | -2.09M | -1.46M | -1.03M | -726.81K | -1.52M |